Rearming antibiotics: AdjuTec Pharma’s fight against antimicrobial resistance

Despite heightened awareness and stricter antibiotic stewardship, treatment options against antimicrobial resistance (AMR) are rapidly diminishing as pathogens evolve faster than new antibiotics can be developed.

Global crises, including conflicts and pandemics, are accelerating this challenge. During the COVID-19 pandemic, up to 80 percent of hospitalized patients received prophylactic antibiotics, contributing to a 15 percent.